Background
Information on clinically verified stroke and transient ischemic attack (TIA) following Hodgkin lymphoma is scarce. We quantified the long-term risk of cerebrovascular disease associated with the use of radiotherapy and chemotherapy in survivors of Hodgkin lymphoma and explored potential pathogenic mechanisms.
Methods
We performed a retrospective cohort study among 2201 five-year survivors of Hodgkin lymphoma treated before age 51 between 1965 and 1995. We compared incidence rates of clinically verified stroke and TIA with those in the general population. We used multivariable Cox regression techniques to study treatmentrelated factors and other risk factors. All statistical tests were two-sided.
especially associated with acute-occurring stroke, possibly because they induce a hypercoagulable state ( 10 -12 ) . These agents are not part of standard treatments for Hodgkin lymphoma, and the longterm effects are not yet defi ned. Furthermore, anthracyclineinduced heart failure ( 13 ) or cardiomyopathy ( 3 , 14 ) could result in an increased risk for stroke and TIA. In females, premature menopause induced by gonadotoxic chemotherapy ( 5 ) may be a risk factor for late-occurring cerebrovascular disease because shorter life span of ovarian activity is associated with an increased risk for ischemic stroke ( 15 ) .
Because the incidence of clinically verifi ed stroke in long-term survivors of Hodgkin lymphoma and the pathogenic mechanisms that contribute to stroke incidence have received so little attention ( 7 , 8 ) , we examined the incidence of both stroke and TIA in a large cohort of Hodgkin lymphoma survivors in the Netherlands. We restricted this study to patients who survived more than 5 years because the risk of vascular events associated with radiotherapy seems to emerge after 5 years or more ( 7 , 9 , 16 ) . The acute effects of the fi rst-line treatment, for example, acute-occurring stroke, are beyond the scope of our study. Unique features of our study include the relatively young age of the cohort (<51 years at diagnosis), clinically verifi ed strokes and TIAs, near-complete follow-up, the assessment of cerebrovascular disease according to radiation fi elds and type of chemotherapy, and the availability of cerebrovascular risk factors.
Subjects and Methods

Data Collection Procedures
We performed a cohort study among patients who were treated at four cancer centers or university hospitals in the Netherlands: the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI/AVL) in Amsterdam, Erasmus Medical Center/Daniel den Hoed Cancer Center (EMC/DdHK) in Rotterdam, Leiden University Medical Center in Leiden, and the Emma Children's Hospital/the Academic Medical Center in Amsterdam. Before our study, patients were identified who were younger than 51 years at treatment for Hodgkin lymphoma (January 1, 1965, to December 31, 1995) with either radiotherapy or chemotherapy. It is estimated that less than 1% of patients were excluded because they had been treated with radiotherapy or chemotherapy before the diagnosis of Hodgkin lymphoma. Patient selection and methods of data collection in NKI/AVL and EMC/DdHK have been described in detail previously ( 1 , 3 , 17 , 18 ) ; similar methods were used in the other centers. Data were collected directly from the medical records. For 775 (34%) of 2253 patients about whom the information could not be obtained from the medical record, questionnaires were sent to general practitioners and attending physicians. Follow-up data for the current study were collected between December 1, 2004, and June 1, 2008. Medical follow-up was complete for 94% of the cohort (of the 2253 patients, 51 patients had moved abroad and 78 were discharged from the primary hospital to undergo treatment elsewhere, where their attending physicians could not be reached). We collected the following information: date of Hodgkin lymphoma diagnosis; treatment modalities of primary as well as salvage treatment for Hodgkin lymphoma (ie, radiation fields, cytostatic agents, and number of cycles); dates of stroke, TIA, and other cardiovascular diseases; cerebrovascular risk factors; age at menopause; date of diagnosis and treatment of second malignancies; and date of most recent medical information or date of death and primary cause of death. Smoking, weight, height, and overweight (body mass index >30) were recorded both at the date of diagnosis of Hodgkin lymphoma and at the end of follow-up. Cerebrovascular risk factors were assessed according to clinical guidelines. Of the 2253 five-year survivors identified, 39 were excluded because follow-up for cardiovascular diseases was less than 5 years following treatment for Hodgkin lymphoma, six were excluded because they developed a second malignancy that was treated with radiotherapy or chemotherapy within the first 5 years following treatment, and another seven individuals were excluded because they developed a stroke or TIA before or within the first 5 years after treatment of Hodgkin lymphoma, leaving 2201 patients eligible for analyses.
Outcome Definition
Cases were defined as cohort members who developed a stroke or TIA 5 years or more after first treatment for Hodgkin lymphoma. Stroke or TIA diagnoses were verified by treating neurologists or general practitioners, who provided additional information on type of stroke (ischemic or hemorrhagic), vascular territory (carotid or vertebrobasilar system), and origin of stroke or TIA. Stroke etiology was further assigned using Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. Subgroups of stroke etiology consisted
CONTEXT AND CAVEATS
Prior knowledge
There have been few studies to date on the long-term influence of treatment for Hodgkin lymphoma on incidence of stroke and transient ischemic attack (TIA).
Study design
The authors studied incidence of stroke and TIA among 2201 fiveyear survivors of Hodgkin lymphoma in the Netherlands. Incidence was stratified by sex, age, treatment period, cerebrovascular risk factors, type of chemotherapy, and radiation field. Hazard ratios (HRs) were calculated on the basis of Cox regression analyses.
Contribution
After a median follow-up of 17.5 years, 96 patients developed cerebrovascular disease: 47 with ischemic strokes, eight with hemorrhagic or unknown strokes, 31 with TIAs, and 10 with ischemic strokes and TIAs. Incidence of stroke was 2.2, and of TIA, was 3.1 times the incidence in the general population. Radiation to the neck and mediastinum was associated with increased risk (HR = 2.5), whereas treatment with chemotherapy was not.
Implications
Most survivors of Hodgkin lymphoma are at increased risk for cerebrovascular events, and risk-reducing strategies should be considered.
Limitations
Precise information on radiation dosage was lacking in this study, and in some cases, the etiology of cerebrovascular events was unknown.
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of large-artery atherosclerosis, cardioembolism, small-vessel occlusion, stroke of other determined etiology, and stroke of undetermined etiology ( 19 ) . We also collected data on treatment and clinical outcome (on average) 3 months after the event according to the Modified Rankin Score (MRS) ( see Table 1 for a detailed description) ( 20 ) . TIA was defined as any new neurological deficit (either ocular or cerebral) that resolved completely within 24 hours ( 14 ) . Stroke was defined as any new neurological deficit (either ocular or cerebral) that persisted longer than 24 hours or ended in death within 30 days ( 14 ) .
Treatment
Dates of primary as well as first salvage treatment with radiotherapy and chemotherapy were recorded, as was detailed information on radiation fields, chemotherapeutic agents, and number of treatment cycles. Patients were usually treated in European Organization for Research and Treatment of Cancer (EORTC) trials or according to EORTC guidelines ( 21 ) .
We classifi ed radiation exposure by assessing individual treatment data for primary as well as salvage treatment regarding the anatomical location of radiation fi elds ( Figure 1 ). Radiotherapy techniques changed over the years. In the 1960s, patients were treated with cobalt-60 or orthovoltage therapy. From the 1970s onward, linear accelerators were used (usually 8 MV photons). Individual blocks were used to shield normal tissues as much as possible. Shielding of the distal part of the mediastinum was sometimes performed from the late 1980s onward if there was no spread of disease below the aortic notch. The vast majority of cervically irradiated patients (82%) received a classical mantle fi eld (at extended source skin distance involving the axillary, mediastinal, and neck nodes), including the common carotid arteries, heart, and thoracic aorta ( Figure 2 ). In addition, most patients were treated at only one fi eld, that is, anatomic location, per day. The procedure of treatment at two fi elds per day was gradually introduced in the late 1980s. Patients usually received 40 Gy (36 -44 Gy) in fractions of 2.0 Gy. Historically, patients were treated to doses of 40 Gy and, in the era that anthracycline-containing chemotherapy was not available (circa the 1980s), they were sometimes reirradiated for recurrences. In addition, compensation for dosage inhomogeneity was not routinely performed until the 1980s, and hotspots in the neck and axilla could be as high as 20% -30% above the prescribed doses ( 22 ) . However, information on radiation techniques, radiation doses, and fractionation schedules for individual patients was not collected.
From the 1960s to the 1980s, chemotherapy consisted mainly of MOPP (mechlorethamine, vincristine, procarbazine, prednisone). In the 1980s, even more effective anthracycline-containing regimens such as MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine) and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) were introduced as a part of the primary treatment.
Statistical Analyses
We compared the incidence of stroke and TIA in the study population with the incidence in the general Dutch population (matched on age, sex, and calendar period), taking into account the number of person-years of observation in the cohort (by age, calendar period, and follow-up interval) ( 3 ) . Incidence data from the Continuous Morbidity Registration -Nijmegen, which are derived from several general practices from representative regions in the Netherlands, were used as reference rates ( 23 ) . This registry has collected data on the incidence of TIA and stroke for the period from 1972 to 2000, allowing for multiple separate diagnoses per person but recording only the first of a specific diagnosis per person. There is no distinction between ischemic and hemorrhagic strokes in this registry. Follow-up started 5 years after the first treatment for Hodgkin lymphoma and ended at date of diagnosis of stroke or TIA, date of diagnosis of a second malignancy treated with radiotherapy or chemotherapy, date of most recent medical information, or date of death, whichever came first. Observed numbers were based on all first events of stroke and TIA that occurred during time at risk. Strokes or TIAs that occurred after treatment of a second malignancy were therefore not included in the analysis.
Hodgkin lymphoma survivors may die from other causes before they can develop cerebrovascular disease, especially with prolonged follow-up. Therefore, we calculated the cumulative incidences of stroke, TIA, and ischemic stroke or TIA combined with adjustment for competing risks of death due to any cause using S-plus statistical software (Insightful, Seattle, WA), including user-written functions ( 24 ) .
The standardized incidence ratios (SIRs) of the observed and expected numbers of stroke and TIA in the study population were determined, and the confi dence intervals (CIs) of the SIRs were calculated using exact Poisson probabilities of observed numbers ( 25 ) . P values for tests for trend were two-sided and were calculated using 2 test statistics. P values less than .05 were considered statistically signifi cant. Absolute excess risk was calculated by subtracting the expected number of strokes or TIAs in the cohort from the number observed and dividing by person-years at risk (expressed per 10 000 person-years).
To study the effects of different treatments taking into account several covariates, we performed multivariate Cox regression analyses. Because the proposed mechanisms for treatment-induced stroke and TIA are thought to cause ischemic events, we excluded hemorrhagic strokes and strokes of unknown type in these analyses. In case of multiple events, time at risk ended at the date of the fi rst stroke or TIA. All treatment-related exposure variables were analyzed as time-dependent variables. We calculated hazard ratios (HRs) as a measure of relative risk (RR) and 95% confi dence intervals to describe the precision of our estimates. We evaluated the proportional hazards assumption by assessing log minus log curve {ln [ Ϫ ln ( S )]} and by fi tting interaction terms between treatment categories and covariates and the logarithm of follow-up time. No violations of the proportional hazards assumption were observed. Models were fi tted with the use of SPSS statistical software (SPSS, Inc, Chicago, IL).
Results
Of the 2201 patients studied, 96 patients developed a stroke or TIA (55 strokes, 31 TIAs, and 10 patients with both a TIA and a stroke) during a median of 17.5-year follow-up ( Table 1 ) . Of the 65 strokes, 57 were ischemic, seven were hemorrhagic (including two subarachnoid hemorrhages), and in one case, the type could not be verified. Median time to first stroke or TIA was 17.4 years (range = 5.1 -37.6 years). When only ischemic events are considered, 88 individuals developed at least one ischemic stroke or TIA (47 of the stroke-only patients suffered ischemic strokes, all 10 of those with both stroke and TIA had ischemic strokes, and 31 patients had only TIAs). Thirty-five of the ischemic strokes and TIAs occurred in patients younger than 51 years ( Table 1 ) . Most ischemic events were either of the large-artery atherosclerotic subtype or of the cardioembolic subtype ( Table 1 ). In 15 (17%) of 88 patients with ischemic events, duplex ultrasonography revealed substantial (>50%) stenosis of the carotid artery. The majority of ischemic strokes and TIAs were pharmacologically treated. Twenty-two percent of the patients suffering from ischemic stroke had a poor clinical outcome ( Table 1 ).
The cumulative incidence of ischemic stroke or TIA, combined, accounting for death as a competing risk 30 years after fi rst treatment, was 7% (95% CI = 5% to 8%) ( Figure 3 ). The separate cumulative incidences of stroke and TIA were 5% (95% CI = 4% to 6%) and 3% (95% CI = 2% to 4%) at that time, respectively.
Compared with the general population, Hodgkin lymphoma survivors experienced an approximately twofold increased risk for stroke (SIR = 2.2; 95% CI = 1.7 to 2.8) and a threefold increased risk for TIA (SIR = 3.1; 95% CI = 2.2 to 4.2), resulting in 12 excess cases of stroke and nine excess cases of TIA per 10 000 persons per year ( Table 2 ). There were statistically signifi cant trends of increasing SIRs with younger age at fi rst treatment ( P = .004 for stroke and P = .01 for TIA), but no increasing or decreasing trends with longer follow-up time or treatment period. There were no clear differences in risk for these cardiovascular problems between men and women who survived Hodgkin lymphoma, and SIRs were only increased among those treated with radiotherapy alone or combined modality treatment ( Table 2 ) .
The multivariable Cox regression analysis showed that patients treated with neck irradiation together with mediastinal irradiation experienced a statistically signifi cantly increased risk for ischemic stroke or TIA, compared with those treated with chemotherapy or infradiaphragmatic irradiation alone (HR = 2.5; 95% CI = 1.1 to 5.6) ( Table 3 ) . Most of these patients (86%) received mantle fi eld irradiation ( Figure 1 ). Neither anthracycline-containing chemotherapy nor other chemotherapy was associated with an increased risk for ischemic cerebrovascular disease. Hypertension was an independent risk factor for ischemic stroke or TIA; hypercholesterolemia and diabetes mellitus were positively but not statistically signifi cantly associated with ischemic cerebrovascular disease. Smoking and overweight were not associated with ischemic stroke or TIA ( Table 3 ) .
We also assessed the association of premature menopause and gonadotoxic chemotherapy with risk of ischemic stroke or TIA following treatment for Hodgkin lymphoma ( Table 4 ) . We did not fi nd any evidence that either premature menopause or gonadotoxic chemotherapy, both of which can be related to cumulative procarbazine exposure ( 5 ), was associated with an increased risk for ischemic stroke and TIA among women ( Table 4 ) .
Of the 1651 patients treated with mediastinal and neck irradiation, 348 (21%) developed cardiac disease (heart failure, myocardial infarction, arrhythmias, or valvular disease) before the occurrence of ischemic stroke, TIA, or end of follow-up. This proportion was substantially lower among those treated with other radiation fi elds or without radiotherapy (56/509 = 11%). However, the risk of developing ischemic stroke or TIA in the period between fi rst treatment for Hodgkin lymphoma and end of follow-up among patients treated with mediastinal and neck irradiation did not differ from the risk in the same period among those who did not develop cardiac disease before end of follow-up (adjusted HR = 0.6; 95% CI = 0.4 to 1.1). However, when patientyears after the occurrence of cardiac disease were compared with patient-years before cardiac disease in a time-dependent analysis, we found that among patients who were treated with mediastinal and neck irradiation, the risk for ischemic stroke or TIA was twofold higher after cardiac disease than before (adjusted HR = 2.1; 95% CI = 1.2 to 3.7).
Discussion
To the best of our knowledge, this is the first long-term cohort study that has assessed the incidence of clinically verified stroke and TIA in survivors of Hodgkin lymphoma, evaluated the contribution of cerebrovascular risk factors as well as of radiation fields, and compared the incidence with that in the general population. Overall, stroke and TIA risks were increased compared with an age-and sex-matched control population. Risks were especially , stroke, and all ischemic cerebrovascular events (TIA and stroke combined) following Hodgkin lymphoma treatment. Solid line , ischemic cerebrovascular events (TIA and stroke combined); dashed line , stroke; dotted line , TIA. The cumulative incidence of ischemic cerebrovascular events (TIA and stroke combined), accounting for death as a competing risk 30 years after treatment, was 7% (95% confi dence interval [CI] = 5% to 8%), that for ischemic stroke was 5% (95% CI = 4% to 6%), and that for TIA was 3% (95% CI = 2% to 4%). At 10 years, the incidence of TIA and stroke was 0.6% (95% CI = 0.3% to 1.0%), that for stroke was 0.5% (95% CI = 0.2% to 0.8%), and that for TIA was 0.2% (95% CI = 0.0% to 0.4%). At 20 years, the incidence of TIA and stroke was 3% (95% CI = 2% to 4%), that for stroke was 2% (95% CI = 2% to 3%), and that for TIA was 2% (95% CI = 1% to 2%). 2 (4) 0 Dead (MRS = 6) 9 (18) 0 * TIA = transient ischemic attack; MRS = Modified Rankin Score. † There were 65 total strokes: seven hemorrhagic, 57 ischemic, and one unidentified. There were 41 total TIAs. These numbers do not include the eight ischemic strokes that occurred after a TIA, nor the two TIAs that occurred after an ischemic stroke. ‡ MRS: 0 = No symptoms at all; 1 = No substantial disability despite symptoms; able to carry out all usual duties and activities; 2 = Slight disability; unable to carry out all previous activities but able to look after own affairs without assistance; 3 = Moderate disability; requiring some help but able to walk without assistance; 4 = Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5 = Severe disability; bedridden, incontinent, and requiring constant nursing care and attention; and 6 = Dead. * TIA = transient ischemic attack; O = observed number of cases; E = expected number of cases; SIR = standardized incidence ratio; AER = absolute excess risk; CI = confidence interval. † Including eight ischemic strokes that occurred after a TIA, seven hemorrhagic strokes, one stroke of unknown type, and two TIAs that occurred after an ischemic stroke. ‡ A 2 test for trend was used for P for trend. § Attained age was defined as the age of patients at diagnosis of a given cerebrovascular event or at the end of follow-up and was calculated to assess at what ages patients experienced increased risk compared with their peers in the general population. Each patient contributed person-years to each consecutive attained-age category that the patient passed through during follow-up.
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elevated among patients who were treated at a young age (<21 years), and they remained increased for at least 25 years. The excess burden of stroke and TIA among Hodgkin lymphoma survivors are 10 and nine cases per 10 000 patients per year, respectively, which amounts to one excess case each of stroke and TIA among hundred 5-year survivors followed for 10 years. Radiation to the neck and mediastinum proved a statistically significant risk factor for the occurrence of ischemic stroke and TIA ( P = .03).
Other statistically significant risk factors were age at treatment ( P < .001) and hypertension ( P = .003). Recently, the Childhood Cancer Survivor Study (CCSS) reported on self-reported incidence and risk factors for stroke among childhood Hodgkin lymphoma survivors ( 7 ). Twentyfour late-occurring strokes were observed in a cohort of 1926 survivors of childhood Hodgkin lymphoma (RR = 4.32; 95% CI = 2.01 to 9.29). Patients irradiated with mantle fi elds even experienced higher relative risks for stroke (RR = 5.62; 95% CI = 2.59 to 12.25). Our results are consistent with the CCSS data, although the relative risks we found are lower than those calculated by the CCSS. A probable explanation is that the CCSS population is younger, and in our data, younger age at fi rst treatment was associated with a greater risk increase of stroke. However, in the youngest group of our cohort, the risk is still lower than reported by CCSS. It is possible that self-report of stroke can lead to overestimation of the true incidence of the disease. For patients, it is diffi cult to distinguish a stroke from other focal neurological disorders like epileptic seizures and collapses.
The most important risk factor for ischemic stroke and TIA in our study was irradiation to the neck and mediastinum. Studies in survivors of head and neck cancers showed that high-dose radiotherapy (60 -66 Gy) to the neck is associated with a substantially increased risk of stroke ( 9 , 16 , 26 ) . The time interval from radiotherapy until stroke diagnosis was shorter in head and neck cancer patients (median time interval = 10.9 years, range = 1.3 -21.0 years) than in the Hodgkin lymphoma survivors (median time interval = 17.4 years, range = 5.1 -37.6 years). We hypothesize that in relatively young Hodgkin lymphoma survivors (median age at first treatment = 27.1, range = 3.1 -50.9 years) with naive atherosclerotic arteries, radiotherapy induces atherosclerosis. In contrast, in the older head and neck cancer patients, radiotherapy accelerates the already existing atherosclerotic lesions. Because radiation effects are presumed to be dose related, mantle field irradiation (with a tumor dose of 30 -40 Gy) may contribute to a longer time interval than the higher dose radiotherapy schedules in head and neck cancer patients.
In concordance with Hull et al. ( 8 ) , who studied risk factors for carotid and subclavian disease among Hodgkin lymphoma patients, we found that hypertension was an independent risk factor for ischemic stroke and TIA. By contrast, we were not able to confi rm the high risk associated with diabetes mellitus. The fact that we did not fi nd an association with diabetes mellitus could be due to coincidence or to the fact that Hull et al. studied a slightly different endpoint, including not only stroke and TIA but also subclinical carotid and subclavian stenosis. * HR = hazard ratio; CI = confidence interval; BMI = body mass index. † Adjusted for age at first treatment for Hodgkin lymphoma, pelvic irradiation, and each other. ‡ Daunorubicin, doxorubicin, epirubicin, gemcitabine, idarubicin, mitoxantrone. § Hypertension, hypercholesterolemia, and diabetes mellitus were scored as positive when stated in the medical information or when treated. Smoking was scored positive when the patient was smoking at the end of follow-up or had stopped smoking less than 1 year before the end of follow-up.
Besides large-artery atherosclerosis, another mechanism for ischemic stroke and TIA in these patients includes cardioembolism. Hodgkin lymphoma survivors have an increased risk of radiotherapy-related cardiovascular disease like myocardial infarction and valvular dysfunction ( 3 , 8 ) . We found that 24% of the ischemic strokes and TIAs had a cardioembolic etiology ( Table 1 ) . We also found that after a patient had developed cardiac disease, the risk of subsequent ischemic stroke or TIA was twofold increased. Epidemiological study of intermediate factors in the etiologic pathway of exposure and disease requires advanced statistical techniques ( 27 ) . Unfortunately, in our study population, numbers were too small to successfully apply these techniques.
Overall, stroke and TIA were diagnosed at a relatively young age (median = 52 years, range = 24 -80 years). The impact of stroke and TIA on quality of life of Hodgkin lymphoma survivors is high. In general, stroke is judged the sixth most common cause of reduced disability-adjusted life years (DALY = sum of life years lost as a result of premature death and years lived with disability adjusted for severity) ( 28 ) . In our cohort, 13% of the patients with ischemic stroke had a poor clinical outcome (MRS ≥ 4). Among patients who suffered ischemic strokes at young ages (aged <51 years at diagnosis), the proportion of patients with a poor clinical outcome was much lower than that among patients who suffered ischemic strokes at older ages (14% vs 29%). Long-term prognosis of ischemic stroke in young adults (range = 15 -45 years) is generally poor (MRS score > 3), especially in terms of work activity: only 53% of young ischemic stroke patients return to work again ( 29 ) . However, functional independence is more common and is typically observed ( 29 ) in 90% of patients, which is comparable with the current study cohort (functional indepen-
Primary prevention for cardiovascular and cerebrovascular disease after radiotherapy has not yet been established. Because cardiovascular risk factors, like hypertension, contribute to the elevated risk of ischemic stroke and TIA after radiotherapy ( 8 , 9 ) , intervention in these risk factors after radiotherapy is important. Secondary preventive strategies after ischemic stroke and TIA in Hodgkin lymphoma survivors are similar to those used for classic atherosclerosis and consist of antiplatelet and anticoagulant treatment according to the origin of stroke (noncardiogenic vs cardiogenic). Special attention is needed for screening of the carotid arteries and for cardioembolisms in case of symptomatic long-term survivors of Hodgkin lymphoma. We do not advocate screening for carotid stenosis in asymptomatic patients because of the relatively low excess cases of stroke and TIA: about one excess case of stroke and TIA each among hundred 5-year survivors followed for 10 years. The best treatment for both asymptomatic and symptomatic carotid artery stenosis is a matter of debate and should be patient tailored. Both carotid endarterectomy and carotid artery stenting could be considered ( 30 ) . Strong features of our study are near-complete follow-up and the validation and outcome of stroke and TIA by information from the neurologist. We found that the proportion of strokes of the ischemic subtype (87%) was slightly higher compared with other population-based series of strokes (54% -88%) ( 31 -34 ) . Another interesting fi nding was the distribution of large-vessel atherosclerosis vs cardioembolic etiology between ischemic strokes (43% vs 18%) and TIAs (28% vs 31%). In addition, substantial carotid stenosis was, at least, present in 20% of the patients who suffered from ischemic stroke and in 13% of the patients who experienced a TIA ( Table 1 ). These proportions might be underestimated because ultrasonography was performed in only 73% of all stroke patients and in 72% of all TIA patients.
Unfortunately, precise information on administered radiation dose was lacking in our study. In the study by Hull et al. ( 8 ) , the median low cervical radiation doses for patients who did and did not develop subclavian stenosis were 44 and 36 Gy, respectively ( P = .002). However, the relative risks of stroke were statistically signifi cantly elevated in patients treated between 1965 and 1985 ( P < .001), whereas the relative risk was not statistically significantly increased in patients treated between 1986 and 1995 ( P = .15; Table 2 ). This fi nding suggests a dose effect, although it may also be due to fewer person-years with long-term follow-up and associated lower power, among patients from the more recent era. The relative risks of TIA, however, were similarly elevated throughout the calendar period of 1965 -1995. Since then, there have been substantial changes in radiation treatment for Hodgkin lymphoma with the use of lower doses, smaller treatment fi elds, and more conformal techniques to limit dosage heterogeneity. It would be interesting to further examine radiation dose -response relationships in future studies that would cover patients treated after 1995, when both applied radiation doses and volume were reduced.
Another limitation of our study is the proportion of missing data regarding the etiology of the ischemic strokes and TIAs (20% unknown). For some very disabled patients (MRS ≥ 4, 13%), the treating neurologists performed no further research to identify the underlying cause of these events. In the remaining patients, we could not retrieve these data.
In summary, patients with Hodgkin lymphoma experience a two-to threefold increased risk of stroke and TIA for a prolonged period after treatment. Radiation to the neck and mediastinum is important contributor to cerebrovascular late effects. For young survivors of Hodgkin lymphoma, who are at especially increased risk of stroke and TIA, physicians should consider appropriate risk-reducing strategies, such as treatment of hypertension and lifestyle changes to reduce the risk of stroke and TIA.
